Login to Your Account

Washington Roundup

Final Rule Draws Line Between Orphan Status and Exclusivity

By Mari Serebrov
Washington Editor

Thursday, June 13, 2013
The FDA etched a distinct line between orphan drug designation and exclusivity in a final rule released Wednesday, making it clear that getting the designation doesn't guarantee seven years of market exclusivity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription